The involvement of the mTOR kinase in the acquisition of the DN T cell phenotype is further documented by a report showing that the treatment of SLE patients with mTOR inhibitor sirolimus/rapamycin can significantly reduce IL-17-producing DN T cell numbers (53). This evidence concerns the gene IL17A and systemic lupus erythematosus.